Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3006)	12/10/2013 2:46:38 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

>> Geron's results don't seem to beat that << Yes, they do. The pathology slides show fat and sassy marrow in some patients, normal marrow. Jakafi takes forever to stabilize fibrosis in a small percentage of patients. That said, I don't expect jakafi to be a stand-alone therapy, and believe that the panobinostat combo is only a first shot. Those who ignore V617F, just because jak inhibitors are not curative? Big mistake.